<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39430203</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2188-2126</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Juntendo Iji zasshi = Juntendo medical journal</Title><ISOAbbreviation>Juntendo Iji Zasshi</ISOAbbreviation></Journal><ArticleTitle>The Effect of Antiplatelet Therapy on COVID-19.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>120</EndPage><MedlinePgn>118-120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14789/jmj.JMJ24-0004-P</ELocationID><Abstract><AbstractText>Platelets are one of the major targets of SARS-CoV-2. Activated platelets release prothrombotic substances, express adhesion molecules, and activate coagulation, thereby contributing to the thrombotic tendency in COVID-19. However, the antiplatelet therapy is not recommended in the current international guidelines. We think that the initiation timing and the target severity are the causes of the failure in clinical trials. As shown in the clinical studies that examined the effects of anticoagulants, early initiation in moderate severity is necessary for the success of antithrombotic therapy. Future trials are warranted to study the effects of antiplatelets in such conditions.</AbstractText><CopyrightInformation>Â© 2024 The Juntendo Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarlatescu</LastName><ForeName>Ecaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Juntendo Iji Zasshi</MedlineTA><NlmUniqueID>9918713988906676</NlmUniqueID><ISSNLinking>2187-9737</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">P2Y12 inhibitor</Keyword><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">platelet</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39430203</ArticleId><ArticleId IdType="pmc">PMC11487358</ArticleId><ArticleId IdType="doi">10.14789/jmj.JMJ24-0004-P</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wada H, Ichikawa Y, Ezaki M, et al. : Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. J Clin Med, 2022; 11: 985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877880</ArticleId><ArticleId IdType="pubmed">35207258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapkiewicz AV, Mai X, Carsons SE, et al. : Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine, 2020; 24: 100434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316051</ArticleId><ArticleId IdType="pubmed">32766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH: Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med, 2022; 32: 249-256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861143</ArticleId><ArticleId IdType="pubmed">35202800</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Connors JM, Levy JH: What Role Does Microthrombosis Play in Long COVID? Semin Thromb Hemost, 2023. doi: 10.1055/s-0043-1774795.</Citation><ArticleIdList><ArticleId IdType="pubmed">37748518</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Sholzberg M, Spyropoulos AC, et al. : ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost, 2022; 20: 2214-2225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349907</ArticleId><ArticleId IdType="pubmed">35906716</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Writing Committee for the REMAP-CAP Investigators : Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA, 2022; 327: 1247-1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941448</ArticleId><ArticleId IdType="pubmed">35315874</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow JH, Rahnavard A, Gomberg-Maitland M, et al. : Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19. JAMA Netw Open, 2022; 5: e223890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8948531</ArticleId><ArticleId IdType="pubmed">35323950</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators : Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med, 2021; 385: 790-802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group : Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 2022; 399: 143-151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM, Brooks MM, Sciurba FC, et al. : Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA, 2021; 326: 1703-1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>